Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has granted market approval for its product Daxxify (daxibotulinumtoxin, RT002). This type A botulinum toxin is now approved for the temporary improvement of moderate to severe eyebrow wrinkles in adults in China, which are caused by the activity of the frown and/or brow muscles.
Developed by U.S. firm Revance Therapeutics, Inc., RT002 is a long-acting neuromodulator created through a proprietary technology platform. It is designed for medical aesthetic purposes, such as improving moderate to severe frown lines in adults, as well as therapeutic uses including adult cervical muscle tone disorders. Fosun Pharmaceutical secured an exclusive licensing agreement with Revance in December 2018, which granted Fosun the rights to use, import, market, and commercialize RT002 in mainland China, Hong Kong, and Macau. The product received approval in the United States for temporarily improving moderate to severe eyebrow wrinkles in adults caused by the activity of the frown and/or brow muscles in September 2022 and for treating cervical muscle tone disorders in adults in August 2023. – Flcube.com
